Abstract

Inducing beta-cell mass expansion in diabetic patients with the aim to restore glucose homeostasis is a promising therapeutic strategy. Although several in vitro studies have been carried out to identify modulators of beta-cell mass expansion, restoring endogenous beta-cell mass in vivo has yet to be achieved. To identify potential stimulators of beta-cell replication in vivo, we established transgenic zebrafish lines that monitor and allow the quantification of cell proliferation by using the fluorescent ubiquitylation-based cell cycle indicator (FUCCI) technology. Using these new reagents, we performed an unbiased chemical screen, and identified 20 small molecules that markedly increased beta-cell proliferation in vivo. Importantly, these structurally distinct molecules, which include clinically-approved drugs, modulate three specific signaling pathways: serotonin, retinoic acid and glucocorticoids, showing the high sensitivity and robustness of our screen. Notably, two drug classes, retinoic acid and glucocorticoids, also promoted beta-cell regeneration after beta-cell ablation. Thus, this study establishes a proof of principle for a high-throughput small molecule-screen for beta-cell proliferation in vivo, and identified compounds that stimulate beta-cell proliferation and regeneration.

Highlights

  • Pancreatic beta-cells secrete insulin which is the only hormone known to directly lower blood glucose concentrations

  • Type 2 diabetes has a multifactorial origin that commences with insulin resistance and increased serum insulin levels followed by beta-cell destruction, insulin deficiency and hyperglycemia [1,2]

  • We found that plasma glucose levels were two folds higher after a 24 hour exposure to prednisolone compared to controls (Fig. 2D), suggesting that the induction of beta-cell proliferation by prednisolone was caused by hyperglycemia

Read more

Summary

Introduction

Pancreatic beta-cells secrete insulin which is the only hormone known to directly lower blood glucose concentrations. Potential strategies for beta-cell mass restoration can generally be categorized as ex vivo strategies involving the generation of betacells from stem cells, either embryonic stem (ES) cells or induced pluripotent stem (iPS) cells, and their subsequent transplantation, as well as in vivo regeneration approaches, including beta-cell mass expansion via reprogramming of other cell types and/or stimulation of proliferation of preexisting beta-cells. It remains unclear which approach will prove successful, and both approaches may even be synergistic [3]

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.